Latest News of BMRN
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now
By Yahoo! Finance |
2 days ago
The article discusses the growing importance of genomics stocks in the market, highlighting BioMarin Pharmaceutical Inc. and the potential of the genomics industry. Cathie Wood emphasizes the revoluti...
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
By Yahoo! Finance |
2 weeks ago
Biomarin Pharmaceutical Inc shows financial growth in its 10-Q report, with a focus on rare-disease therapies. Despite revenue increase, rising operating expenses require careful management. Market le...
Biomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
By Yahoo! Finance |
3 weeks ago
BMN 333 aims to enhance CNP's half-life for improved effects in skeletal disorders. The trial length and expansion into other indications are flexible based on data. Factors impacting financials inclu...
-
BioMarin Pharmaceutical (BMRN): Hedge Funds Back Biotech Leader Amid Record Revenue Growth
By Yahoo! Finance | 4 weeks agoGoldman Sachs predicts a drop in S&P 500 returns due to market concentration in top stocks. They suggest the growth rate will decline as it's hard to sustain high levels for long. Despite this, they f...
-
BioMarin Pharmaceutical Inc. (BMRN): Is This Biotech Stock A Good Buy?
By Yahoo! Finance | 2 months agoThe article discusses the top biotech stocks to invest in, focusing on BioMarin Pharmaceutical Inc. It highlights the growth potential of the biotechnology industry, market trends, stock analysis, and...
-
BioMarin Pharmaceutical Inc (BMRN): Are Hedge Funds Bullish on This Elliott Management-Approved Stock Now?
By Yahoo! Finance | 3 months agoElliott Management's top 10 stock picks include BioMarin Pharmaceutical Inc (BMRN). The hedge fund, led by billionaire Paul Singer, is known for successful investments in underperforming companies and...
-
Here's Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN)
By Yahoo! Finance | 4 months agoParnassus Investments' "Parnassus Value Equity Fund" outperformed the Russell 1000 Value Index in Q1 2024. Key contributors were stock selections in IT and Communication sectors. BioMarin Pharmaceutic...
-
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 41% Below Their Intrinsic Value Estimate
By Yahoo! Finance | 4 months agoThe fair value estimate for BioMarin Pharmaceutical is 32% higher than the analyst price target. Using a 2-stage DCF model, the intrinsic value is estimated at US$27 billion, indicating the stock is u...
-
Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback?
By Yahoo! Finance | 5 months agoScout Investments, Inc, under Carillon Tower Advisers, released the Q1 2024 investor letter for the "Carillon Scout Mid Cap Fund." The letter discusses market trends, highlights like BioMarin Pharmace...